Zelluna’s core asset is a wide range of TCRsisolated from patients who exhibited long-term survival following inclusion in peptide-based cancer vaccine trials initiated by Prof Gustav Gaudernack and conducted by investigators at the Norwegian Radium Hospital/Oslo University Hospital. Currently, the company has several TCRs in different stages of development. Zelluna Immunotherapy is a biopharma company developing “off-the-shelf” T-cell receptor (TCR) guided natural killer (NK) cell therapy products for the treatment of multiple solid cancers.
$ 5 Millions - $ 10 Millions
Leave a Reply